The National Institutes of Health has made significant updates to its guidelines on treating people with COVID-19. What’s New in the Guidelines Last Updated: April 21, 2021 The Coronavirus Disease 2019 (COVID-19) Treatment Guidelines is published in an electronic format that can be updated in step with the rapid pace and growing volume of information regarding the
COVID-19, caused by SARS-CoV-2 virus infection, has changed human behavior patterns since it became a global pandemic. To date, more than 136 million people have suffered from the disease and, of these, more than 2.9 million have lost their lives. The symptoms of the infection vary widely, from individuals who show no clinical symptoms to those who
Cases of unusual thrombosis and thrombocytopenia after administration of the ChAdOx1 nCoV‐19 vaccine (AstraZeneca) have been reported. The term vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT) was coined to reflect this new phenomenon. In vitro experiments with VIPIT patient sera indicated that high dose intravenous immunoglobulins (IVIG) competitively inhibit the platelet activating properties of ChAdOx1 nCoV‐19 vaccine induced
In a paper recently published on Cell, an emerging SARS-CoV-2 variant was identified by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California, a state in the Western United States. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged in May 2020 and increased from 0% to >50% of sequenced
At its meeting of 20 April 2021, EMA’s safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine. In reaching its conclusion, the Committee took into
For weeks, Americans looked on as other countries grappled with case reports of rare, sometimes fatal blood abnormalities among those who had received the AstraZeneca vaccine against COVID-19. That vaccine has not yet been authorized by the FDA, so restrictions on its use throughout Europe did not get that much attention in the United States.
The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a year, several vaccines have been developed and millions of doses delivered. Reporting of adverse events is a critical postmarketing activity. In this paper are reported findings in 23 patients who presented with
Despite progress in clinical care for patients with coronavirus disease 2019 (COVID-19), population-wide interventions are still crucial to manage the pandemic, which has been aggravated by the emergence of new, highly transmissible variants. In this study, we combined the SIDARTHE model, which predicts the spread of SARS-CoV-2 infections, with a newdata-based model that projects new
Researchers at the University of Oxford have today reported that the risk of the rare blood clotting known as cerebral venous thrombosis (CVT) following COVID-19 infection is around 100 times greater than normal, several times higher than it is post-vaccination or following influenza. The study authors, led by Professor Paul Harrison and Dr Maxime Taquet
The use of this vaccine in several countries in South America and eastern Europe, besides Russia, mandates that its efficacy against the new resistant variants be tested, as they are being found more commonly in these regions.Generation of replication-competent VSV bearing SARS-CoV-2 spike (rcVSV-CoV2-S). (A) Schematic of the rcVSV-CoV2-S genomic coding construct and the virus
